No Detail Found!

Serum copper level as a predictive marker in patients of malignant cancerous prostate and benign prostatic hyperplasia (BPH) along with its correlation to serum acid phosphatase.

Author(s)
Naheed Qadir Department of Biochemistry, Peoples University of Medical & Health Sciences,Nawabshah-67450,Pakistan
Jalil Qadir Department of Forensic medicine & Toxicology, Liaquat college of Medicine &Dentistry,Karachi-75290,Pakistan
Jamil Ahmed Siddiqui Department of Biochemistry, Al Tibri Medical College,Karachi,Pakistan
Abstract
The objective of present study was to estimate and compare the serum copper level in patients with benign prostatic hypertrophy and prostate carcinoma and their correlation with serum acid phosphatase. Prostatic acid phosphatase for Group A was 2.28 ± 0.99, for Group B 16.03 ± 5.89 and for Group c 46.43 ± 6.22 U/L, respectively. Highly significant P- value of 0.0001 was noted among all the 3 groups; A, B and C. Serum copper levels in Group A 106.88 ± 19.28, Group B 104.29 ± 17.40 and Group C 92.88 ± 11.28µg/L, respectively. P value between groups A vs B, A vs C and B vs C were noted as 0.052, 0.001 and 0.022, respectively. Serum copper was reduced in group B compared to A, but P value showed no significant difference (p=0.052). However, A vs C and B vs C showed statistically significant differences. The present study reports the raised prostatic acid phosphatase, and decreased serum copper levels in carcinoma of prostate gland indicating their diagnostic and prognostic significance.
Publication Details
Page(s) 23-26
DOI DOI not available
Published Journal: International Journal of Biology and Biotechnology, Volume: 16, Issue: 1, Year: 2019

Request the full text from PASTIC

Keywords
Prostate carcinoma, Prostate acid phosphatase, benign prostatic hyperplasia, serum copper
0

Citations

0

Downloads

21

Views